Contrasting BetterLife Pharma (OTCMKTS:PVOTF) and Lifecore Biomedical (NASDAQ:LFCR)

Lifecore Biomedical (NASDAQ:LFCR) and BetterLife Pharma (OTCMKTS:PVOTF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Profitability

This table compares Lifecore Biomedical and BetterLife Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-12.52%	-315.23%	-12.74%
BetterLife Pharma	N/A	-205.15%	-147.23%

Insider and Institutional Ownership

83.4% of Lifecore Biomedical shares are held by institutional investors. 32.2% of Lifecore Biomedical shares are held by insiders. Comparatively, 34.8% of BetterLife Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Lifecore Biomedical and BetterLife Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	0	2	1	0	2.33
BetterLife Pharma	0	0	0	0	0.00

Lifecore Biomedical presently has a consensus price target of $8.00, suggesting a potential upside of 16.79%. Given Lifecore Biomedical’s stronger consensus rating and higher probable upside, equities analysts plainly believe Lifecore Biomedical is more favorable than BetterLife Pharma.

Earnings & Valuation

This table compares Lifecore Biomedical and BetterLife Pharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$130.86 million	1.94	$12.01 million	($0.56)	-12.23
BetterLife Pharma	N/A	N/A	-$14.78 million	N/A	N/A

Lifecore Biomedical has higher revenue and earnings than BetterLife Pharma.

Summary

Lifecore Biomedical beats BetterLife Pharma on 7 of the 11 factors compared between the two stocks.

About Lifecore Biomedical

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

About BetterLife Pharma

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.